Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 2/20 | 0.48 |
| ▸ | ALOX5AP | P20292 | 13/20 | 0.45 |
| ▸ | FEN1 | P39748 | 13/20 | 0.45 |
| ▸ | EDNRB | P24530 | 4/20 | 0.44 |
| ▸ | EDNRA | P25101 | 4/20 | 0.44 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1968159 | 0.84 | ALOX5AP (0.59) | CASP1ALOX5APFEN1EDNRBEDNRA | |
| SCHEMBL15668311 | 0.79 | CASP1 (0.51) | CASP1ALOX5APFEN1EDNRBEDNRA | |
| SCHEMBL1767981 | 0.77 | CA2 (0.58) | CASP1EDNRBEDNRAUCHL1USP30 | |
| SCHEMBL29537027 | 0.77 | CA2 (0.58) | CASP1EDNRBEDNRAUCHL1USP30 | |
| SCHEMBL8997291 | 0.77 | CASP1 (0.50) | CASP1EDNRBEDNRA | |
| SCHEMBL17978509 | 0.77 | PTGS2 (0.50) | — | |
| SCHEMBL6820374 | 0.76 | EDNRA (0.56) | CASP1ALOX5APFEN1EDNRBEDNRA | |
| SCHEMBL1846856 | 0.76 | CASP1 (0.51) | CASP1ALOX5APFEN1EDNRBEDNRA | |
| SCHEMBL418847 | 0.76 | CASP1 (0.51) | CASP1ALOX5APFEN1EDNRBEDNRA | |
| SCHEMBL10780146 | 0.76 | CASP1 (0.51) | CASP1ALOX5APFEN1EDNRBEDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004043917-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-05-27 | — | — | WO | claimed |
| US-9884878-B2 | FLAP modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-02-06 | — | — | US | disclosed |
| US-9745328-B2 | Flap modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-29 | — | — | US | disclosed |
| US-20150376212-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-31 | — | — | US | disclosed |
| US-20150353538-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150259357-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-17 | — | — | US | disclosed |
| US-9079866-B2 | Flap modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-14 | — | — | US | disclosed |
| US-20140221311-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (US) | 2014-08-07 | — | — | US | disclosed |
| US-20130317027-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| EP-2542086-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | Myrexis, Inc. (US) | 2013-01-09 | — | — | EP | disclosed |
| US-20120329786-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-12-27 | — | — | US | disclosed |
| WO-2011109441-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
| WO-2004043917-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353538-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | NFATC1, CD47, CD4 | CASP1 331/4885ALOX5AP 329/4885FEN1 4481/4885 |
| US-20150376212-A1 | FLAP MODULATORS | FEN1, PGF, TBXA2R | CASP1 1208/4885ALOX5AP 95/4885FEN1 1/4885 |
| US-20120329786-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | NFATC1, CD47, CD4 | CASP1 331/4885ALOX5AP 329/4885FEN1 4481/4885 |
| US-20150259357-A1 | FLAP MODULATORS | PGF, FEN1, TBXA2R | CASP1 2012/4885ALOX5AP 80/4885FEN1 2/4885 |
| US-20130317027-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | NFATC1, CD47, CD4 | CASP1 331/4885ALOX5AP 329/4885FEN1 4481/4885 |
| US-20140221311-A1 | FLAP MODULATORS | PGF, FEN1, TBXA2R | CASP1 2012/4885ALOX5AP 80/4885FEN1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.